1 / 11

Antipsychotic Prescribing in the treatment of Schizophrenia Karen Hayhurst

Antipsychotic Prescribing in the treatment of Schizophrenia Karen Hayhurst ERC, Wythenshawe Hospital. UK Prevalence Antipsychotic Combination Prescribing. Inpatients 48% 1-day audit (n=3132) Harrington et al 2002 50.5% 1-day audit (n=3576) Lelliott et al 2002

evelyn
Download Presentation

Antipsychotic Prescribing in the treatment of Schizophrenia Karen Hayhurst

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antipsychotic Prescribing in the treatment of Schizophrenia Karen Hayhurst ERC, Wythenshawe Hospital

  2. UK PrevalenceAntipsychotic Combination Prescribing Inpatients • 48% 1-day audit (n=3132) Harrington et al 2002 • 50.5% 1-day audit (n=3576) Lelliott et al 2002 • 37% 1-month audit (n=107) Chaplin & McGuigan 1996 Community patients • 33% (n=52,884) Shepherd et al 2003 • Large UK variation 12% to 71% Harrington et al 2002 • Duration of AP poly mean = 4 years (up to 18 years) Waddington et al 1998

  3. Local PrevalenceCombination Antipsychotic Prescribing (1998)

  4. Local Prevalence (2005) Audit of Antipsychotic Prescribing - Oldham

  5. Local Prevalence (2005) Audit of Antipsychotic Prescribing - Pennine Care

  6. Link between AP co-prescribing & high dose prescribing • AP co-prescribing leads to likelihood of receiving a combined high dose • A pt prescribed >1 AP drug has 41x the odds of being prescribed a high dose than a pt prescribed a single AP drug Lelliott et al 2002 - Mean dose of AP mono = 210.7 CPZeq - Mean dose of AP poly = 406.8 CPZeq Bingefors et al 2003 - US inpatient study = AP dose 78% higher for those on AP combinations than on AP monotherapy Centorrino et al 2004 • Incidence = 20% of UK pts receive AP drugs in doses exceeding BNF guidance Bebbington 2001

  7. Adverse events related to Antipsychotic Co-prescribing • Prescribers not aware of additive side-effects resulting from AP polypharmacy Maudsley guidelines 2005-2006 • When FGA and SGAs combined, patients are put at risk for both the old and new adverse effects Yuzda 2000 • Atypical AP polypharmacy inc probability of receiving anti-EPS treatment 2-fold Carnahan et al 2006 • Patients prescribed FGA + SGA together more likely to be prescribed regular anticholinergic meds compared with patients receiving a SGA alone = higher rates of EPS Taylor et al 2000 • No therapeutic advantages & significant increase in adverse reactions with doses > 375 mg CPZeq Bollini et al 1994 • Use of high AP doses leads to a high incidence of SEs + may be associated with sudden cardiac death as AP drugs cause QTc lengthening in a dose-related manner Pathare & Paton 1997 Reilly et al 2000 • Receiving >1 AP concurrently associated with reduced survival Waddington et al 1998 • Patients are less adherent to complex medical regimes than simpler regimes Chen 1991

  8. Treatment Guidelines – UK Royal College of Psychiatrists’ consensus statement on high dose AP prescribing (revised, May 2006) “the efficacy of combining 2 or more FGAs or adding a FGA to a SGA (or vice versa) has not been established + there is evidence for increased risk of adverse effects and pharmacokinetic interactions” “current state of knowledge does not allow for any plausible pharmacological rationale for high-dose AP medication” NICE guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia (2002) “atypical & typical AP drugs not to be prescribed concurrently, except for short periods to cover changeover of meds” “high doses may increase likelihood of side effects + thus may limit benefit by reduction in concordance” NICEcore interventions in the treatment and management of schizophrenia in primary & secondary care (2002) “best to use a single drug, using doses within BNF dose range and not to use high or loading doses” “the addition of a second AP to clozapine may be considered for people with TRS for whom clozapine has proved insufficiently effective” BNF (British National Formulary 2006) “prescribing of >1 AP at the same time is not recommended; it may constitute a hazard” “consider high-dose therapy to be for a limited period - abandon if no improvement after 3m + return to standard dosage” Maudsley prescribing guidelines (2005-2006) “AP monotherapy is desirable and should be the norm” “polypharmacy should be undertaken only where response to a single AP (including clozapine) has been clearly demonstrated to be inadequate - in such cases, the effect of polypharmacy should be carefully evaluated and documented - where there is no clear benefit, treatment should revert to single AP therapy”

  9. Treatment Guidelines – US APAPractice Guideline (American Psychiatric Association 2nd Edition 2004) “practitioners should be aware of problems inherent in combination therapies, including increased costs + decreased adherence” “higher doses are no more effective for acute treatment than normal doses, but are associated with greater incidence of side effects” IPAP(CINP-International Psychopharmacology Algorithm Project - Meltzer et al updated 2006) “monotherapy is a core recommendation of this algorithm” “rapid high-dose AP treatment is almost never warranted” TMAP(Texas Medication Algorithm Project, Miller et al 1999; updated 2004) “there is no evidence to support the use of AP polypharmacy before a trial of clozapine has been attempted” “augmentation of clozapine remains the best treatment option for patients whose schizophrenic symptoms fail to respond or only partially respond to an adequate trial of clozapine monotherapy” PORT(Patient Outcomes Research Team, Lehman & Steinwachs 1998) “the dosage of AP medication for an acute symptom episode should be in the range of 300-1000 cpzeq per day for a minimum of 6 weeks - reasons for dosages outside this range should be justified” “massive loading doses of AP medication, referred to as ‘rapid neuroleptization’, should not be used”

  10. Can antipsychotic prescribing be changed? • SiGMA(Schizophrenia in Greater Manchester) audits Tameside (1999/ 2000) & South Manchester (2001): – where guidelines used, AP co-prescribing rates <20% vs. >30% in previous audits • CUtLASS (cost-utility of the latest antipsychotics in severe schizophrenia) N=363 - 24% rate of AP co-prescribing at baseline - 14% rate of AP co-prescribing at one year (end of study) Lewis et al 2006 • Systematic review- studies which have tried to change prescribing behaviour Wide variation in effect of interventions on AP prescribing Relatively small changes in AP co-prescribing as a result of interventions: - 2.1% decrease Glikman 2000 - 14.4% difference in rates of change between intervention and control groups Thompson 2006 AP drug dose - moderate to large changes as a result of interventions - 30% reduction in mean cpzeq dose Warner 1995

  11. Summary • UK prevalence AP co-prescribing - wide variation (30-50%) • Local prevalence AP co-prescribing – 1998 audit (30-50%) • Oldham audit (N=389) - AP co-prescribing = 23% - high dose AP prescribing = 14% • Pennine Care audit (N=815) - link between AP poly & high dose prescribing - indication of pt characteristics associated with AP co-prescribing/ high dose prescribing - association with anticholinergic use as indicative of incidence of SEs • Concerns re associated adverse events • All available treatment guidelines guard against the use of combination AP prescribing (except for closely monitored addition of a 2nd AP drug to clozapine in TRS) & high dose prescribing • Evidence that AP prescribing can be changed • Controlled trials of AP co-prescribing needed so risks vs benefits can be determined Freudenreich & Goff 2002; Miller & Craig 2002; Stahl & Grady 2004; Tapp 2005

More Related